Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 18, 2015; 7(29): 2913-2919
Published online Dec 18, 2015. doi: 10.4254/wjh.v7.i29.2913
Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C
Andrea Martini, Andrea Gallotta, Patrizia Pontisso, Giorgio Fassina
Andrea Martini, Patrizia Pontisso, Department of Medicine, University of Padua, 35122 Padua, Italy
Andrea Gallotta, Giorgio Fassina, Xeptagen S.p.A., VEGA Science Park, 30175 Marghera, Venice, Italy
Author contributions: Martini A designed the study, acquired the data and drafted the article; Gallotta A made critical comments and reviewed the manuscript; Pontisso P and Fassina G conceived the study and made the final critical revision of the manuscript; all authors have seen and approved the final version of the manuscript.
Conflict-of-interest statement: Fassina G (Chief Scientific Officer) and Gallotta A (Senior Scientist) are employees of Xeptagen S.p.A.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Dr. Giorgio Fassina, Xeptagen S.p.A., VEGA Science Park, Building Auriga, Via delle Industrie 9, 30175 Marghera, Venice, Italy.
Telephone: +39-041-5093910
Received: July 10, 2015
Peer-review started: July 12, 2015
First decision: September 8, 2015
Revised: September 30, 2015
Accepted: December 1, 2015
Article in press: December 2, 2015
Published online: December 18, 2015
Core Tip

Core tip: A high public health priority need is the development of biomarkers to screen for liver disease progression in hepatitis C virus (HCV)-positive patients. Serological squamous cell carcinoma antigen-immunoglobulins M has shown the ability to identify patients with progressive liver disease and patients at higher risk of hepatocellular carcinoma development. In this review we summarize the main clinical studies performed using this new circulating biomarker for monitoring cirrhosis progression in HCV-positive patients and to evaluate virological response to antiviral treatment.